tert-butyl-(5-methyl-[1,3,4]thiadiazol-2-yl)-amine | 38917-38-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: tert-butyl-(5-methyl-[1,3,4]thiadiazol-2-yl)-amine
• 英文别名: 1,3,4-Thiadiazol-2-amine, N-tert-butyl-5-methyl-；N-tert-butyl-5-methyl-1,3,4-thiadiazol-2-amine
• CAS: 38917-38-3
• 化学式: C₇H₁₃N₃S
• 分子量: 171.266
• InChiKey: DSUZZNDRCQQWFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-acetyl-4-tert-butyl-thiosemicarbazide 在 硫酸 作用下， 生成 tert-butyl-(5-methyl-[1,3,4]thiadiazol-2-yl)-amine
  参考文献：
  名称：

  Svanholm,U., Acta Chemica Scandinavica (1947-1973), 1972, vol. 26, p. 459 - 467

  摘要：

  DOI：

文献信息

• IDO inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US10689331B2

  公开（公告）日：2020-06-23

  There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

  本发明公开了调节或抑制吲哚胺-2,3-二氧化酶（IDO）酶活性的化合物、含有上述化合物的药物组合物以及利用本发明化合物治疗增殖性疾病（如癌症、病毒感染和/或炎症性疾病）的方法。
• 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
  申请人：Kaufman L. Mildred

  公开号：US20070054933A1

  公开（公告）日：2007-03-08

  Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
• N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
  申请人：Array BioPharma Inc.

  公开号：US20210008023A1

  公开（公告）日：2021-01-14

  This invention provides compounds of Formula I wherein B, G, A, E, R 1 , R 3 , R 4 , m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
• SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE
  申请人：Shuttle Pharmaceuticals, Inc.

  公开号：US20210078963A1

  公开（公告）日：2021-03-18

  Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
• US7446110B2
  申请人：——

  公开号：US7446110B2

  公开（公告）日：2008-11-04